Research ArticleArticle
Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor
Aditya J. Desai, Ingrid Mechin, Karthigeyan Nagarajan, Celine Valant, Denise Wootten, Polo C. H. Lam, Andrew Orry, Ruben Abagyan, Anil Nair, Patrick M. Sexton, Arthur Christopoulos and Laurence J. Miller
Molecular Pharmacology March 2019, 95 (3) 245-259; DOI: https://doi.org/10.1124/mol.118.114082
Aditya J. Desai
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Ingrid Mechin
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Karthigeyan Nagarajan
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Celine Valant
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Denise Wootten
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Polo C. H. Lam
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Andrew Orry
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Ruben Abagyan
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Anil Nair
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Patrick M. Sexton
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Arthur Christopoulos
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Laurence J. Miller
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (A.J.D., L.J.M.); In Silico Drug Discovery Department, Icagen Tucson Innovation Center, Oro Valley, Arizona (I.M., K.N., A.N.); Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Australia (C.V., D.W., P.M.S., A.C., L.J.M.); Molsoft, La Jolla, California (P.C.H.L., A.O., R.A.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California (R.A.); and School of Pharmacy, Fudan University, Shanghai, China (D.W., P.M.S.)
Article Information
vol. 95 no. 3 245-259
PubMed
Print ISSN
Online ISSN
Article Versions
- Earlier version (December 27, 2018 - 09:01).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics
Statistics from Altmetric.com
Article usage
In this issue
Research ArticleArticle
CCK Receptor PAM Agonist
Aditya J. Desai, Ingrid Mechin, Karthigeyan Nagarajan, Celine Valant, Denise Wootten, Polo C. H. Lam, Andrew Orry, Ruben Abagyan, Anil Nair, Patrick M. Sexton, Arthur Christopoulos and Laurence J. Miller
Molecular Pharmacology March 1, 2019, 95 (3) 245-259; DOI: https://doi.org/10.1124/mol.118.114082
Research ArticleArticle
CCK Receptor PAM Agonist
Aditya J. Desai, Ingrid Mechin, Karthigeyan Nagarajan, Celine Valant, Denise Wootten, Polo C. H. Lam, Andrew Orry, Ruben Abagyan, Anil Nair, Patrick M. Sexton, Arthur Christopoulos and Laurence J. Miller
Molecular Pharmacology March 1, 2019, 95 (3) 245-259; DOI: https://doi.org/10.1124/mol.118.114082
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement